Limits...
Cost and effectiveness of omega-3 fatty acid supplementation in Chinese ICU patients receiving parenteral nutrition.

Wu GH, Gao J, Ji CY, Pradelli L, Xi QL, Zhuang QL - Clinicoecon Outcomes Res (2015)

Bottom Line: The model predicted that omega-3 PUFA-enriched emulsion (Omegaven(®) 10% fish oil emulsion) would dominate standard lipid emulsions, with better clinical outcomes and lower overall health care costs (mean savings ~10,000 RMB), mainly as a result of faster recovery and shorter hospital stay (by ~6.5 days).The external validation process confirmed the reliability of the model predictions.Omega-3 PUFA-enriched lipid emulsions improved clinical outcome and decreased overall costs in Chinese ICU patients requiring PN.

View Article: PubMed Central - PubMed

Affiliation: Department of General Surgery, Fudan University, Shanghai, People's Republic of China.

ABSTRACT

Background and objectives: Clinical evidence supports the use of omega-3 polyunsaturated fatty acid (PUFA)-enriched lipid emulsions in place of standard lipid emulsions in parenteral nutrition (PN) for intensive care unit (ICU) patients, but uptake may be limited by higher costs. We compared clinical and economic outcomes for these two types of lipid emulsion in the Chinese ICU setting.

Methods: We developed a pharmacoeconomic discrete event simulation model, based on efficacy data from an international meta-analysis and patient characteristics, resource consumption, and unit costs from a Chinese institutional setting. Probabilistic sensitivity analyses were undertaken to assess the effects of uncertainty around input parameters. Model predictive validity was assessed by comparing results with data observed in a patient subset not used in the modeling.

Results: The model predicted that omega-3 PUFA-enriched emulsion (Omegaven(®) 10% fish oil emulsion) would dominate standard lipid emulsions, with better clinical outcomes and lower overall health care costs (mean savings ~10,000 RMB), mainly as a result of faster recovery and shorter hospital stay (by ~6.5 days). The external validation process confirmed the reliability of the model predictions.

Conclusion: Omega-3 PUFA-enriched lipid emulsions improved clinical outcome and decreased overall costs in Chinese ICU patients requiring PN.

No MeSH data available.


Related in: MedlinePlus

Scatterplot of the incremental cost and avoided infections for the Omegaven® versus the standard arm on a cost-effectiveness plane.Abbreviations: O-3, Omegaven-3; ST, standard; ICER, incremental cost-effectiveness ratio; pt, patient; PSA, probabilistic sensitivity analyses.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4492652&req=5

f2-ceor-7-369: Scatterplot of the incremental cost and avoided infections for the Omegaven® versus the standard arm on a cost-effectiveness plane.Abbreviations: O-3, Omegaven-3; ST, standard; ICER, incremental cost-effectiveness ratio; pt, patient; PSA, probabilistic sensitivity analyses.

Mentions: Omegaven® is expected to dominate standard PN in this patient population, as it is associated with a mean increase in effectiveness with a concurrent decrease in mean costs. Results of the 1,000 PSA iterations are represented graphically on a cost-effectiveness plane in Figure 2. Most observations (88%) are in the south-west quadrant, indicating negative incremental costs and negative incremental infections, ie, showing dominance of the Omegaven® arm.


Cost and effectiveness of omega-3 fatty acid supplementation in Chinese ICU patients receiving parenteral nutrition.

Wu GH, Gao J, Ji CY, Pradelli L, Xi QL, Zhuang QL - Clinicoecon Outcomes Res (2015)

Scatterplot of the incremental cost and avoided infections for the Omegaven® versus the standard arm on a cost-effectiveness plane.Abbreviations: O-3, Omegaven-3; ST, standard; ICER, incremental cost-effectiveness ratio; pt, patient; PSA, probabilistic sensitivity analyses.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4492652&req=5

f2-ceor-7-369: Scatterplot of the incremental cost and avoided infections for the Omegaven® versus the standard arm on a cost-effectiveness plane.Abbreviations: O-3, Omegaven-3; ST, standard; ICER, incremental cost-effectiveness ratio; pt, patient; PSA, probabilistic sensitivity analyses.
Mentions: Omegaven® is expected to dominate standard PN in this patient population, as it is associated with a mean increase in effectiveness with a concurrent decrease in mean costs. Results of the 1,000 PSA iterations are represented graphically on a cost-effectiveness plane in Figure 2. Most observations (88%) are in the south-west quadrant, indicating negative incremental costs and negative incremental infections, ie, showing dominance of the Omegaven® arm.

Bottom Line: The model predicted that omega-3 PUFA-enriched emulsion (Omegaven(®) 10% fish oil emulsion) would dominate standard lipid emulsions, with better clinical outcomes and lower overall health care costs (mean savings ~10,000 RMB), mainly as a result of faster recovery and shorter hospital stay (by ~6.5 days).The external validation process confirmed the reliability of the model predictions.Omega-3 PUFA-enriched lipid emulsions improved clinical outcome and decreased overall costs in Chinese ICU patients requiring PN.

View Article: PubMed Central - PubMed

Affiliation: Department of General Surgery, Fudan University, Shanghai, People's Republic of China.

ABSTRACT

Background and objectives: Clinical evidence supports the use of omega-3 polyunsaturated fatty acid (PUFA)-enriched lipid emulsions in place of standard lipid emulsions in parenteral nutrition (PN) for intensive care unit (ICU) patients, but uptake may be limited by higher costs. We compared clinical and economic outcomes for these two types of lipid emulsion in the Chinese ICU setting.

Methods: We developed a pharmacoeconomic discrete event simulation model, based on efficacy data from an international meta-analysis and patient characteristics, resource consumption, and unit costs from a Chinese institutional setting. Probabilistic sensitivity analyses were undertaken to assess the effects of uncertainty around input parameters. Model predictive validity was assessed by comparing results with data observed in a patient subset not used in the modeling.

Results: The model predicted that omega-3 PUFA-enriched emulsion (Omegaven(®) 10% fish oil emulsion) would dominate standard lipid emulsions, with better clinical outcomes and lower overall health care costs (mean savings ~10,000 RMB), mainly as a result of faster recovery and shorter hospital stay (by ~6.5 days). The external validation process confirmed the reliability of the model predictions.

Conclusion: Omega-3 PUFA-enriched lipid emulsions improved clinical outcome and decreased overall costs in Chinese ICU patients requiring PN.

No MeSH data available.


Related in: MedlinePlus